Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients

Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients - Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018162

Enrollment

Registered

2015-07-02

Start date

2014-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with esophageal cancer, undergoing chemotherapy

Interventions

In ghrelin group (n=20), patients with esophageal cancer were recieved intravenous synthetic human ghrelin (0.5 micro g/kg/h) administration for 5 days from a day ago of DCF. In control group (n=20),

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with primary esophageal cancer planned DCF chemotherapy; 2. creatinine clearance > 60 ml/min; 3. No renal disease; 4. no previous treatment; 5. age; 20-80 years; 6. adequate function of major organs; 7. Eastern Cooperative Oncology Group performance status (PS) score of 0 or 1; 8. provision of written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with severe co morbid conditions 2. other active malignancy 3. judged as inappropriate by physician-in-charge 4. combination with radiation therapy 5. lactation and pregnancy

Design outcomes

Primary

Measure	Time frame
serum creatinine level	—

Secondary

Measure	Time frame
adverse events serum cystatin C level hormone measurement (ghrelin, growth hormone, Insulin-like growth factor-1) outcomes of 2nd cycle chemotherapy	—

Countries

Japan

Contacts

Public ContactYoshitomo Yanagimoto

Osaka University School of Medicine Gastroenterological Surgery

yoshitomo-0225@outlook.com06-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026